Tissue-Resident Type 2 Innate Lymphoid Cells Arrest Alveolarization in Bronchopulmonary Dysplasia

J Immunol Res. 2020 Oct 31:2020:8050186. doi: 10.1155/2020/8050186. eCollection 2020.

Abstract

Bronchopulmonary dysplasia (BPD) is a severe complication of the respiratory system associated with preterm birth. Type 2 innate lymphoid cells (ILC2s) play a major role in tissue homeostasis, inflammation, and wound healing. However, the role in BPD remains unclear. The present study showed that ILC2s, interleukin-4 (IL-4), IL-13, and anti-inflammatory (M2) macrophages increased significantly in BPD mice as compared to the control mice. Administration with recombinant mouse IL-33 amplified the above phenomena and aggravated the alveolar structural disorder and functional injury in mice subjected to BPD, and the opposite was true with anti-ST2 antibody. In addition, the depletion of ILC2s in BPD mice with anti-CD90.2 antibody substantially abolished the destructive effect on BPD. In the treatment of BPD with dexamethasone, the number of ILC2s and M2 macrophages and levels of IL-4 and IL-13 decreased with remission as compared to the control group. This study identified a major destructive role of the ILC2s in BPD that could be attenuated as a therapeutic strategy.

MeSH terms

  • Animals
  • Biomarkers
  • Bronchopulmonary Dysplasia / etiology*
  • Bronchopulmonary Dysplasia / metabolism*
  • Bronchopulmonary Dysplasia / pathology
  • Cytokines
  • Dexamethasone / pharmacology
  • Disease Models, Animal
  • Disease Susceptibility
  • Female
  • Immunity, Innate*
  • Immunophenotyping
  • Lymphocytes / drug effects
  • Lymphocytes / immunology*
  • Lymphocytes / metabolism*
  • Macrophages / immunology
  • Macrophages / metabolism
  • Mice
  • Pulmonary Alveoli / immunology*
  • Pulmonary Alveoli / metabolism*
  • Pulmonary Alveoli / pathology

Substances

  • Biomarkers
  • Cytokines
  • Dexamethasone